XML 72 R60.htm IDEA: XBRL DOCUMENT v3.25.2
Investments Accounted for Using the Equity Method - Summary of Key Items Which Have Not Been Audited (Details) - Associates and joint ventures - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure of transactions between related parties [line items]    
Sales (c) (d) [1],[2] € 29 € 59
Other Comprehensive Income, Related Party Disclosures (1)  
Comprehensive Income 23  
Amounts payable, related party transactions 19,116  
Current assets, Related Party Transactions 2,937  
Assets, Related Party Transactions 19,116  
Equity Attributable to Equity Holders, Related Party Transactions 5,754  
Equity Attributable to Non Controlling Interest, Related Party Transactions 541  
Equity, Related Party Transactions 6,295  
Non Current Liabilities, Related Party Transactions 11,039  
Current Liabilities, Related Party Transactions 1,782  
Liabilities, Related Party Transactions 12,821  
Non Current assets, Related Party Transactions 16,179  
Net Income [3] 24  
Net Sales and Other Revenues [3] € 887  
[1]
(c)    Figures for 2024 comparative periods have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2]
(d) For the six months ended June 30, 2025, these amounts include transactions between Sanofi and OPAL JV Co for the period from May 1, 2025 through June 30, 2025.
[3] With effect from May 1, 2025, OPAL JV Co is accounted for using the equity method following the loss of control of Opella by Sanofi on April 30, 2025.